Skip to content
Clinical Trials – home

Azienda Ospedaliero-Universitaria Maggiore Della Carita

Verified siteinfo

Italy Corso Giuseppe Mazzini 18, 28100 Novara, Italy

  • 105 trials recruiting
  • Chronic lymphocytic leukaemia · Non-small cell lung cancer · Plasma cell myeloma
  • Adults and children

About Specializations

Azienda Ospedaliero-Universitaria Maggiore Della Carita in Novara, Italy specialises in clinical trials of conditions such as Chronic lymphocytic leukaemia, Non-small cell lung cancer, Plasma cell myeloma, Breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Neurology and Neurodegenerative Disease Research

At Azienda Ospedaliero-Universitaria Maggiore Della Carita, the Department of Neurology and ALS Center support studies focused on nervous system diseases and related quality-of-life outcomes. Research includes major conditions such as Amyotrophic Lateral Sclerosis, Alzheimer’s disease, and Parkinson’s disease, with trials aimed at testing new symptom-relief approaches and improving daily functioning.

  • Neurodegenerative disease management, including ALS, Alzheimer’s disease, and Parkinson’s disease
  • Evaluation of treatments designed to improve quality of life and patient comfort
  • Supportive care research in a specialist neurology setting

The site’s neurology expertise also connects with broader work on neurological complications and brain-related outcomes, reflecting a strong focus on practical, patient-centered care.

Hematology and Lymphoma Studies

This research program includes several trials in hemic and lymphatic diseases, especially follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma. The studies are designed to compare new immunotherapies and targeted treatments with current standards of care, with the goal of improving disease control and response rates.

  • Relapsed or refractory follicular lymphoma and marginal zone lymphoma
  • Newly diagnosed and previously treated aggressive B-cell lymphoma
  • Multiple myeloma and chronic lymphocytic leukemia treatment strategies

These trials show a strong interest in advancing blood cancer care through more effective and better-tolerated therapies.

Breast Cancer and Other Solid Tumor Research

The site is active in neoplasms, with studies in early breast cancer, advanced breast cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, and prostate cancer. Research here often aims to determine whether newer hormone-based, immune-based, or targeted approaches can improve progression-free survival and reduce recurrence.

  • ER-positive, HER2-negative breast cancer in early and advanced settings
  • Non-small cell lung cancer with specific molecular features
  • Prostate cancer and head and neck cancer treatment optimization

These oncology studies reflect a broad effort to refine treatment effectiveness across both common and more specialized cancer types.

Metabolic, Liver, and Cardiovascular Research

Clinical trials at this center also cover nutritional and metabolic diseases, digestive system diseases, and cardiovascular diseases. Key conditions include obesity, type 2 diabetes, MASH, NASH, heart failure, and atrial fibrillation, with studies focused on improving long-term risk reduction, liver health, and cardiometabolic outcomes.

  • Obesity, overweight, and type 2 diabetes management
  • Liver disease research in NASH and MASH with fibrosis
  • Heart failure and stroke prevention in cardiovascular disease

These trials combine prevention and treatment goals, aiming to better control chronic disease progression and associated complications.

Inflammatory, Autoimmune, and Kidney Disease Research

The site also conducts studies in immune system diseases and related inflammatory conditions, including lupus nephritis, autoimmune disease, fibrosis, and chronic kidney disease. The main purpose of this research is to evaluate whether targeted therapies can reduce inflammation, protect organ function, and improve clinical outcomes.

  • Lupus nephritis and other immune-mediated kidney conditions
  • Autoimmune and inflammatory disease treatment evaluation
  • Fibrosis-related disease progression and organ protection

These investigations add an important translational dimension to the Novara research portfolio, linking immune control with better long-term health outcomes.

Ophthalmology and Public Health-Oriented Studies

In addition to specialty disease areas, the research portfolio includes eye diseases such as glaucoma, as well as studies with environment and public health relevance. These trials aim to improve visual preservation, support safer care strategies, and evaluate therapies that may have broader quality-of-life benefits.

  • Glaucoma research focused on preserving vision
  • Public health-oriented clinical studies with patient-centered outcomes
  • Supportive care approaches that may improve everyday functioning

Across these areas, the site combines focused specialty care with broader efforts to improve outcomes that matter to patients in daily life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Corso Giuseppe Mazzini 1828100 NovaraItaly
Recruiting now
105 trials
Conditions studied
160
Partner status
Verified site

More sites in NovaraItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

253 clinical trials

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Breast cancer

Recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Obesity+1

Recruiting

Study on the Effectiveness and Safety of Orforglipron for Weight Management in Adolescents with Obesity or Overweight

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Sponsor:Eli Lilly & Co.

Study on the Effects of Pegozafermin for Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100
  • Sponsor:F. Hoffmann-La Roche AG

Study of Pegozafermin Treatment for Patients with Liver Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sargramostim
  • Sponsor:Greenwich LifeSciences Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.